Exploring the FDA’s draft guidance on AI in regulatory decision-making
In January 2025, the Food and Drug Administration (FDA) issued long-awaited draft guidance on the use of artificial intelligence (AI) in regulatory decision-making for drugs and biological products. In this blog, the Boyds Regulatory Affairs team outlines the new guidance and its aims. The draft guidance, titled ‘Considerations for the Use of Artificial Intelligence […]
